Neurocytoprotective effects of aliphatic hydroxamates from lovastatin, a secondary metabolite from monascus -fermented red mold rice, in 6-hydroxydopamine (6-OHDA)-Treated Nerve Growth Factor (NGF)-Differentiated PC12 Cells

ACS Chemical Neuroscience

Volumn 6, Issue 5, 2015, Pages 716-724

  Lin, Chien Min ^a,b   Lin, Yi Tzu ^a   Lin, Rong Dih ^c   Huang, Wei Jan ^a,d,e   Lee, Mei Hsien ^a,d,f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d PhD Program for the Clinical Drug Discovery from Botanical Herbs   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

6 hydroxydopamine; Lovastatin derived hydroxamate; mitochondrial membrane potential; neurocytoprotective; Parkinson's disease

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ALIPHATIC COMPOUND; CALCIUM ION; CARBOCYANINE; CASPASE 3; CASPASE 9; CHOLESTIN; FLUORESCEIN ISOTHIOCYANATE; HYDROXAMIC ACID; LIPOCORTIN 5; LOVASTATIN DERIVATIVE; MEVINOLIN; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL DIFFERENTIATION; CELL PROTECTION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MONASCUS; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; PARKINSON DISEASE; PC12 CELL LINE; PRIORITY JOURNAL; PROPIDIUM IODIDE ASSAY; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; CELL SURVIVAL; DRUG EFFECTS; NERVE CELL; ORYZA; PARKINSONISM; RAT;

MONASCUS;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL SURVIVAL; LOVASTATIN; MODELS, BIOLOGICAL; MONASCUS; NERVE GROWTH FACTOR; NEURONS; NEUROPROTECTIVE AGENTS; ORYZA; OXIDOPAMINE; PARKINSONIAN DISORDERS; PC12 CELLS; RATS;

EID: 84930199996     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500275k     Document Type: Article

References (51)

1. Roy, A. and Pahan, K. (2011) Prospects of statins in Parkinson disease Neuroscientist 17, 244-255
2. Earhart, G. M. and Falvo, M. J. (2013) Parkinson disease and exercise Compr. Physiol. 3, 833-848
3. Gazewood, J. D., Richards, D. R., and Clebak, K. (2013) Parkinson disease: an update Am. Fam. Physician 87, 267-273
4. Sanders, L. H. and Greenamyre, J. T. (2013) Oxidative damage to macromolecules in human Parkinson disease and the rotenone model Free Radicals Biol. Med. 62, 111-120
5. Tian, X., Sui, S., Huang, J., Bai, J. P., Ren, T. S., and Zhao, Q. C. (2014) Neuroprotective effects of Arctium lappa L. roots against glutamate-induced oxidative stress by inhibiting phosphorylation of p38, JNK and ERK 1/2 MAPKs in PC12 cells Environ. Toxicol. Pharmacol. 38, 189-198
6. Sykora, P., Wilson, D. M., 3rd, and Bohr, V. A. (2013) Base excision repair in the mammalian brain: implication for age related neurodegeneration Mech. Ageing Dev. 134, 440-448
7. Hanrott, K., Gudmunsen, L., O'Neill, M. J., and Wonnacott, S. (2006) 6-Hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta J. Biol. Chem. 281, 5373-5382
8. Soria, G., Aguilar, E., Tudela, R., Mullol, J., Planas, A. M., and Marin, C. (2011) In vivo magnetic resonance imaging characterization of bilateral structural changes in experimental Parkinson's disease: A T2 relaxometry study combined with longitudinal diffusion tensor imaging and manganese-enhanced magnetic resonance imaging in the 6-hydroxydopamine rat model Eur. J. Neurosci. 33, 1551-1560
9. Endo, A. and Hasumi, K. (1993) HMG-CoA reductase inhibitors Nat. Prod. Rep. 10, 541-550
10. Alberts, A. W., Chen, J., Kuron, G., Hunt, V., Huff, J., Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., Harris, E., Patchett, A., Monaghan, R., Currie, S., Stapley, E., Albers-Schonberg, G., Hensens, O., Hirshfield, J., Hoogsteen, K., Liesch, J., and Springer, J. (1980) Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent Proc. Natl. Acad. Sci. U. S. A. 77, 3957-3961
11. Endo, A. (1979) Monacolin K, a new hypocholesterolemic agent produced by a Monascus species J. Antibiot. 32, 852-854
12. Lee, C. L., Kung, Y. H., Wu, C. L., Hsu, Y. W., and Pan, T. M. (2010) Monascin and ankaflavin act as novel hypolipidemic and high-density lipoprotein cholesterol-raising agents in red mold dioscorea J. Agric. Food Chem. 58, 9013-9019
13. Corsini, A., Maggi, F. M., and Catapano, A. L. (1995) Pharmacology of competitive inhibitors of HMG-CoA reductase Pharmacol. Res. 31, 9-27
14. Davignon, J. and Laaksonen, R. (1999) Low-density lipoprotein-independent effects of statins Curr. Opin. Lipidol. 10, 543-559
15. Lee, S. J., Ha, M. J., Lee, J., Nguyen, P., Choi, Y. H., Pirnia, F., Kang, W. K., Wang, X. F., Kim, S. J., and Trepel, J. B. (1998) Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells J. Biol. Chem. 273, 10618-10623
16. Lee, J., Lee, I., Park, C., and Kang, W. K. (2006) Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells Biochem. Biophys. Res. Commun. 339, 748-754
17. Weitberg, A. B. (2007) The antioxidant effect of lovastatin on phagocyte-induced DNA damage: implications for cancer prevention J. Exp. Clin. Cancer Res. 26, 583-586
18. Chen, L., Haught, W. H., Yang, B., Saldeen, T. G., Parathasarathy, S., and Mehta, J. L. (1997) Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine J. Am. Coll. Cardiol. 30, 569-575
19. Elkind, M. S., Sacco, R. L., Macarthur, R. B., Peerschke, E., Neils, G., Andrews, H., Stillman, J., Corporan, T., Leifer, D., Liu, R., and Cheung, K. (2009) High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART) Cerebrovasc. Dis. 28, 266-275
20. Dolga, A. M., Nijholt, I. M., Ostroveanu, A., ten Bosch, Q., Luiten, P. G. M., and Eisel, U. L. M. (2008) Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways J. Alzheimer's Dis. 13, 111-122
21. Elkind, M. S. V., Sacco, R. L., MacArthur, R. B., Fink, D. J., Peerschke, E., Andrews, H., Neils, G., Stillman, J., Corporan, T., Leifer, D., and Cheung, K. (2008) The neuroprotection with statin therapy for acute recovery trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke Int. J. Stroke 3, 210-218
22. van der Most, P. J., Dolga, A. M., Nijholt, I. M., Luiten, P. G. M., and Eisel, U. L. M. (2009) Statins: Mechanisms of neuroprotection Prog. Neurobiol. 88, 64-75
23. Botti, R. E., Triscari, J., Pan, H. Y., and Zayat, J. (1991) Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects Clin. Neuropharmacol. 14, 256-261
24. Saheki, A., Terasaki, T., Tamai, I., and Tsuji, A. (1994) In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors Pharm. Res. 11, 305-311
25. Tsuji, A., Saheki, A., Tamai, I., and Terasaki, T. (1993) Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier J. Pharmacol. Exp. Ther. 267, 1085-1090
26. Aniya, Y., Ohtani, I. I., Higa, T., Miyagi, C., Gibo, H., Shimabukuro, M., Nakanishi, H., and Taira, J. (2000) Dimerumic acid as an antioxidant of the mold, Monascus anka Free Radical Biol. Med. 28, 999-1004
27. Adgent, M. A., Squadrito, G. L., Ballinger, C. A., Krzywanski, D. M., Lancaster, J. R., and Postlethwait, E. M. (2012) Desferrioxamine inhibits protein tyrosine nitration: mechanisms and implications Free Radical Biol. Med. 53, 951-961
28. Sato, E., Kohno, M., Nakashima, T., and Niwano, Y. (2008) Ciclopirox olamine directly scavenges hydroxyl radical Int. J. Dermatol. 47, 15-18
29. Meng, L., Jiang, A., Chen, R., Li, C. Z., Wang, L., Qu, Y., Wang, P., Zhao, Y., and Chen, C. (2013) Inhibitory effects of multiwall carbon nanotubes with high iron impurity on viability and neuronal differentiation in cultured PC12 cells Toxicology 313, 49-58
30. Lin, Y. P., Chen, T. Y., Tseng, H. W., Lee, M. H., and Chen, S. T. (2009) Neural cell protective compounds isolated from Phoenix hanceana var. formosana Phytochemistry 70, 1173-1181
31. Bove, J. and Perier, C. (2012) Neurotoxin-based models of Parkinson's disease Neuroscience 211, 51-76
32. Johnson-Anuna, L. N., Eckert, G. P., Keller, J. H., Igbavboa, U., Franke, C., Fechner, T., Schubert-Zsilavecz, M., Karas, M., Muller, W. E., and Wood, W. G. (2005) Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex J. Pharmacol. Exp. Ther. 312, 786-793
33. Saito, Y., Nishio, K., Ogawa, Y., Kinumi, T., Yoshida, Y., Masuo, Y., and Niki, E. (2007) Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action Free Radical Biol. Med. 42, 675-685
34. Tao, L., Li, X., Zhang, L., Tian, J., Li, X., Sun, X., Li, X., Jiang, L., Zhang, X., and Chen, J. (2011) Protective effect of tetrahydroxystilbene glucoside on 6-OHDA-induced apoptosis in PC12 cells through the ROS-NO pathway PLoS One 6, e26055
35. Bulat, N. and Widmann, C. (2009) Caspase substrates and neurodegenerative diseases Brain Res. Bull. 80, 251-267
36. Viswanath, V., Wu, Y., Boonplueang, R., Chen, S., Stevenson, F. F., Yantiri, F., Yang, L., Beal, M. F., and Andersen, J. K. (2001) Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease J. Neurosci. 21, 9519-9528
37. Butterick, T. A., Igbavboa, U., Eckert, G. P., Sun, G. Y., Weisman, G. A., Muller, W. E., and Wood, W. G. (2010) Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells Mol. Neurobiol. 41, 384-391
38. Franke, C., Noldner, M., Abdel-Kader, R., Johnson-Anuna, L. N., Gibson Wood, W., Muller, W. E., and Eckert, G. P. (2007) Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment Neurobiol. Dis. 25, 438-445
39. Johnson-Anuna, L. N., Eckert, G. P., Franke, C., Igbavboa, U., Muller, W. E., and Wood, W. G. (2007) Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein J. Neurochem. 101, 77-86
40. Yan, J. Q., Ma, Y. J., Sun, J. C., Bai, S. F., and Huang, L. N. (2014) Neuroprotective effect of lovastatin by inhibiting NMDA receptor1 in 6-hydroxydopamine treated PC12 cells Int. J. Clin. Exp. Med. 7, 3313-3319
41. Fonseca, A. C., Proenca, T., Resende, R., Oliveira, C. R., and Pereira, C. M. (2009) Neuroprotective effects of statins in an in vitro model of Alzheimer's disease J. Alzheimer's Dis. 17, 503-517
42. Liu, M., Xu, Y., Han, X., Liang, C., Yin, L., Xu, L., Qi, Y., Zhao, Y., Peng, J., and Sun, C. (2014) Potent effects of flavonoid-rich extract from Rosa laevigata Michx fruit against hydrogen peroxide-induced damage in PC12 cells via attenuation of oxidative stress, inflammation and apoptosis Molecules 19, 11816-11832
43. Liu, C. S., Chen, N. H., and Zhang, J. T. (2007) Protection of PC12 cells from hydrogen peroxide-induced cytotoxicity by salvianolic acid B, a new compound isolated from Radix Salviae miltiorrhizae Phytomedicine 14, 492-497
44. Das, K. P., Freudenrich, T. M., and Mundy, W. R. (2004) Assessment of PC12 cell differentiation and neurite growth: a comparison of morphological and neurochemical measures Neurotoxicol. Teratol. 26, 397-406
45. Greene, L. A. and Tischler, A. S. (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor Proc. Natl. Acad. Sci. U. S. A. 73, 2424-2428
46. Taniguchi, H., Yamamoto, H., Akutsu, N., Nosho, K., Adachi, Y., Imai, K., and Shinomura, Y. (2007) Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer J. Pathol. 213, 131-139
47. Lin, C. M., Lin, R. D., Chen, S. T., Lin, Y. P., Chiu, W. T., Lin, J. W., Hsu, F. L., and Lee, M. H. (2010) Neurocytoprotective effects of the bioactive constituents of Pueraria thomsonii in 6-hydroxydopamine (6-OHDA)-treated nerve growth factor (NGF)-differentiated PC12 cells Phytochemistry 71, 2147-2156
48. Xiong, X. I., Jia, R. H., Yang, D. P., and Ding, G. H. (2006) Irbesartan attenuates contrast media-induced NRK-52E cells apoptosis Pharmacol. Res. 54, 253-260
49. Villa, P., Kaufmann, S. H., and Earnshaw, W. C. (1997) Caspases and caspase inhibitors Trends Biochem. Sci. 22, 388-393
50. Lin, Y. J., Lai, C. C., Lai, C. H., Sue, S. C., Lin, C. W., Hung, C. H., Lin, T. H., Hsu, W. Y., Huang, S. M., Hung, Y. L., Tien, N., Liu, X., Chen, C. L., and Tsai, F. J. (2013) Inhibition of enterovirus 71 infections and viral IRES activity by Fructus gardeniae and geniposide Eur. J. Med. Chem. 62, 206-213
51. Yue, G. G., Chan, B. C., Hon, P. M., Lee, M. Y., Fung, K. P., Leung, P. C., and Lau, C. B. (2010) Evaluation of in vitro anti-proliferative and immunomodulatory activities of compounds isolated from Curcuma longa Food Chem. Toxicol. 48, 2011-2020